Liminal Biosciences Inc (LMNL) |
|
4.19 0.18 (4.49%)
|
03-07 04:27 |
|
Open: |
4.05 |
Pre. Close: |
4.01 |
|
High:
|
4.22 |
Low:
|
3.7 |
|
Volume:
|
438,059 |
Market Cap:
|
123M |
|
|
|
|
Liminal BioSciences, Inc. is a biopharmaceutical corporation. The company is headquartered in Laval, Quebec and currently employs 487 full-time employees. The firm is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. The company operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.224 - 4.244 |
4.244 - 4.262 |
|
Low:
|
3.656 - 3.677 |
3.677 - 3.696 |
|
Close:
|
4.155 - 4.191 |
4.191 - 4.223 |
|
Technical analysis |
as of: 2021-03-05 5:10:20 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.67  One year: 8.12 |
| Support: |
Support1: 3.70 Support2: 3.08 |
| Resistance: |
Resistance1: 5.71 Resistance2: 6.95 |
| Pivot: |
5.26 |
| Moving Average: |
MA(5): 4.51 MA(20): 5.37
MA(100): 4.98 MA(250): 8.37 |
| MACD: |
MACD(12,26): -0.20 Signal(9): |
| Stochastic oscillator: |
%K(14,3): 10.01  %D(3): 8.36 |
| RSI: |
RSI(14): 37.23 |
| 52-week: |
High: 31.45 Low: 3.51 Change(%): -43.9 |
| Average Vol(K): |
3-Month: 131521 10-Days: 55487 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.LMNL has closed above bottom band by 10.7%. Bollinger Bands are 13% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 01 Mar 2021
Should You Buy Liminal BioSciences Inc (LMNL) Stock Monday Morning? - InvestorsObserver
Fri, 19 Feb 2021
Premarket Mover: Liminal BioSciences Inc (LMNL) Up 4.29% - InvestorsObserver
Wed, 10 Feb 2021
Liminal BioSciences Inc (LMNL) Up 20.04% in Premarket Trading - InvestorsObserver
Mon, 08 Feb 2021
Should You Buy Liminal BioSciences Inc (LMNL) Stock on Monday? - InvestorsObserver
Wed, 27 Jan 2021
Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics - PRNewswire
Tue, 12 Jan 2021
Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center - Yahoo Finance
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
29 |
| Shares Float (M) |
20 |
|
% Held by Insiders
|
67.66 |
|
% Held by Institutions
|
6.78 |
|
Shares Short (K)
|
400 |
|
Shares Short P. Month (K)
|
893 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-41.7 |
|
Return on Equity (ttm)
|
-175.5 |
|
Qtrly Rev. Growth
|
-22.8 |
|
Gross Profit (p.s.)
|
-2.483 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
